Chemed Reports Mixed Q4 Results, Issues Strong 2026 EPS Guidance and Announces Significant Share Repurchase

summarizeSummary

Chemed Corporation reported a mixed fourth quarter for 2025, with consolidated revenue remaining flat and both GAAP and Adjusted Diluted EPS declining. However, the company provided robust guidance for 2026, projecting a notable increase in Adjusted Diluted EPS to a range of $23.25-$24.25, up from $21.55 in 2025. This positive outlook is significantly bolstered by an estimated reduction in VITAS's Medicare Cap billing limitations from $27.2 million in 2025 to $9.5 million in 2026, signaling a resolution to a key segment headwind. Additionally, the company demonstrated strong capital allocation by repurchasing $174.6 million in stock during the quarter, indicating management's confidence in future performance. Investors should monitor the execution of the 2026 guidance, particularly the expected second-half weighting of earnings and the recovery in the Roto-Rooter segment.

check_boxKey Events

• Mixed Q4 2025 Financial Performance

  Consolidated revenue was $639.3 million, essentially flat year-over-year. GAAP Diluted EPS decreased 9.0% to $5.48, and Adjusted Diluted EPS decreased 6.0% to $6.42.

• Strong 2026 EPS Guidance

  The company forecasts full-year 2026 Adjusted Diluted EPS in the range of $23.25 to $24.25, a significant increase from $21.55 in 2025. Earnings trajectory is weighted towards the second half of the year.

• Significant Share Repurchase

  Chemed repurchased 400,000 shares of its stock for $174.6 million during the fourth quarter of 2025, with approximately $127.3 million remaining under its authorization plan.

• Improved VITAS Outlook with Reduced Medicare Cap

  VITAS Healthcare is estimated to see its Medicare Cap billing limitations decrease significantly to $9.5 million in calendar 2026, down from $27.2 million in 2025, with revenue expected to increase 5.5% to 6.5%.

auto_awesomeAnalysis

Chemed Corporation reported a mixed fourth quarter for 2025, with consolidated revenue remaining flat and both GAAP and Adjusted Diluted EPS declining. However, the company provided robust guidance for 2026, projecting a notable increase in Adjusted Diluted EPS to a range of $23.25-$24.25, up from $21.55 in 2025. This positive outlook is significantly bolstered by an estimated reduction in VITAS's Medicare Cap billing limitations from $27.2 million in 2025 to $9.5 million in 2026, signaling a resolution to a key segment headwind. Additionally, the company demonstrated strong capital allocation by repurchasing $174.6 million in stock during the quarter, indicating management's confidence in future performance. Investors should monitor the execution of the 2026 guidance, particularly the expected second-half weighting of earnings and the recovery in the Roto-Rooter segment.